New combo aims to boost breast cancer remission rates
Disease control
Not yet recruiting
This study tests a personalized approach for people with stage II or III triple-negative breast cancer. Participants first receive 12 weeks of standard chemo plus the immunotherapy pembrolizumab. Those whose tumors shrink well stop treatment early; others are randomly assigned to…
Phase: PHASE3 • Sponsor: West German Study Group • Aim: Disease control
Last updated May 01, 2026 15:59 UTC